Q3 2024 Earnings Estimate for Coya Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:COYA)

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at HC Wainwright issued their Q3 2024 earnings estimates for Coya Therapeutics in a research report issued on Monday, September 16th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.41) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.38) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.48) EPS.

Other analysts have also issued research reports about the company. Rodman & Renshaw started coverage on Coya Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $18.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, June 5th.

Coya Therapeutics Stock Performance

Coya Therapeutics stock opened at $6.11 on Thursday. Coya Therapeutics has a 52 week low of $3.21 and a 52 week high of $10.69. The firm has a market capitalization of $89.32 million, a PE ratio of -7.19 and a beta of 0.58. The business’s 50-day simple moving average is $6.28 and its 200-day simple moving average is $7.54.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $3.43 million for the quarter.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Gilbert & Cook Inc. acquired a new position in Coya Therapeutics in the second quarter worth about $61,000. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the second quarter worth $101,000. AIGH Capital Management LLC increased its holdings in shares of Coya Therapeutics by 92.6% in the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after purchasing an additional 496,183 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the last quarter. Finally, Greenlight Capital Inc. lifted its position in Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after purchasing an additional 805,959 shares during the period. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.